Immuneering share price logo

Immuneering

NASDAQ: IMRX

$3.75

-0.27

(-6.84%)

as on

Immuneering Stock Performance

as on November 2, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $3.72
    $4.07
    downward going graph

    0.80%

    Downside

    8.53%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.38
    $8.48
    downward going graph

    9.87%

    Downside

    126.13%

    Upside

    downward going graph

Immuneering share price movements today

Previous Close
$4.02
Open
$4.04
Volume
1.1M
Market Cap
$242.5M
Day's Low - High
$3.72 - $4.07
52 Week Low - High
$3.38 - $8.48

Immuneering Historical Returns

1 Month Return
-7.99 %
3 Month Return
-9.32 %
1 Year Return
-45.49 %
3 Year Return
-37.58 %
5 Year Return
-87.07 %

Immuneering Stock Fundamentals & Key Indicators

Check Immuneering market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$242.5M

EPS (TTM)

-1.03

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.64

Industry PE ratio

-3.13

PEG Ratio

-0.06

EBITDA

-72.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-33.91%

Immuneering vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immuneering with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$242.5M-87.07%-3.640.00%0.00%
Neutral$88.5B-36.40%-27.78-12.57%0.00%
StrongBuy$141.7B208.09%32.2786.04%0.00%
Buy$95.5B45.26%19.7685.77%0.40%

Stock Returns calculator for Immuneering Stock including INR - Dollar returns

The Immuneering stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Immuneering investment value today

Current value as on today

₹58,416

Returns

-₹41,584

(-41.58%)

Returns from Immuneering Stock

-₹45,415 (-45.41%)

Dollar Impact

₹3,831 (+3.83%)

Analyst Recommendation on Immuneering Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Immuneering. Average target price of $17

Immuneering Share Price Target

Get share price movements and forecasts by analysts on Immuneering.

What analysts predicted

77.94%UPSIDE

Target Price

$17

Current Price

$3.75

Analyzed by

4 Analysts

High

$18

Target

$17.00

Low

$11

Immuneering target price $17, a slight upside of 77.94% compared to current price of $3.75. According to 4 analysts rating.

Indian Investors' Interest in Immuneering Stock

Search interest for Immuneering Stock has decreased by -66% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-66% versus previous 30 day period

Immuneering Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
0
-
0
-
0
0
-
0
Operating Income
-14
-15
-18
-15
-14
-15
-13
-15
-19
-25
EBITDA
-14
-15
-17
-15
-14
-15
-14
-15
-17
-25
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-14
-14
-18
-15
-14
-14
-11
-13
-17
-24
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-14
-14
-18
-15
-14
-14
-11
-13
-17
-24
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Immuneering Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
2
2
0
-
-
-
Gross Profit
0
1
0
0
-
-
0
Operating Income
-6
-17
-33
-51
-58
-64
-59
EBITDA
-7
-17
-33
-51
-58
-63
-55
Interest Expense
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
Income Before Tax
-7
-17
-33
-50
-53
-61
-56
Income Tax Expense
-
0
0
-
-
-
-
Net Income
-7
-17
-33
-50
-53
-61
-56
Net Profit Margin
36.29%
44.61%
44.56%
50.11%
0.00%
0.00%
0.00%

Immuneering Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-14
-14
-18
-15
-14
-14
-11
-13
-17
-54,893
Operating Cash Flow
-11
-13
-14
-14
-9
-11
-9
-18
-16
-51,685
Investing Cash Flow
4
-5
5
0
0
0
-88
-63
10
-19,071
Financing Cash Flow
-
4
0
13
0
213
0
0
0
0
Change in Cash
-6
-14
-9
0
-9
201
-98
-81
-5
58,185

Immuneering Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-7
-17
-33
-50
-53
-61
-56
Operating Cash Flow
-4
-14
-30
-44
-48
-54
-45
Investing Cash Flow
0
0
-75
41
7
26
-88
Financing Cash Flow
17
37
144
0
28
5
226
Change in Cash
12
23
37
-2
-13
-23
92

Global Institutional Holdings in Immuneering

Check out the Institutions with significant holdings in Immuneering.

Funds
Holdings
Fidelity Mt. Vernon Street Trust
6.94%
Benjamin J. Zeskind
4.96%
iShares
4.10%
Vanguard
4.08%
VANGUARD INDEX FUNDS
3.46%

Immuneering News & Key Events

    Insights on Immuneering

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Moderna, Inc. Common Stock has given 211.3% return, outperforming this stock by 248.9%

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Moderna, Inc. Common Stock has given 716.3% return, outperforming this stock by 761.8%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 4 quarters, -11.58M → -24.19M (in $), with an average decrease of 28.2% per quarter

    • imgNEGATIVE IMPACT

      Price Dip

      img

      In the last 6 months, IMRX stock has moved down by -30.3%

    • imgNEGATIVE IMPACT

      Revenue Fall

      img

      Revenue is down for the last 2 quarters, 726.32K → 360.95K (in $), with an average decrease of 50.3% per quarter

    About Immuneering

    Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
    OrganisationImmuneering
    Headquarters245 Main Street, Cambridge, MA, 02142, US
    IndustryBiotechnology
    CEOBenjamin J. Zeskind

    Key Management of Immuneering

    Name

    Title

    Dr. Benjamin J. Zeskind M.B.A., Ph.D.

    Co-Founder, President, CEO & Director

    Mr. Robert J. Carpenter M.B.A., M.S.

    Co-Founder & Chair Emeritus

    Dr. Brett M. Hall Ph.D.

    Chief Scientific Officer

    Ms. Paula George CPA

    Senior Director of Accounting & Operations and Assistant Corporate Controller

    Ms. Mallory Morales CPA

    Senior VP of Finance, Chief Accounting Officer & Assistant Treasurer

    Mr. Michael D. Bookman J.D.

    Chief Legal Officer & Secretary

    Mr. Andrew W. Gengos

    CFO & Treasurer

    Ms. Jyoti Joshi

    Director of Quality Systems & Compliance

    Mr. David Caouette

    Vice President of Corporate Communications

    Ms. Leah R. Neufeld

    Chief People Officer

    FAQs

    What is Immuneering share price today?

    Immuneering share price today is $3.75 as on at the close of the market. Immuneering share today touched a day high of $4.07 and a low of $3.72.

    What is the 52 week high and 52 week low for Immuneering share?

    Immuneering share touched a 52 week high of $8.48 on and a 52 week low of $3.38 on . Immuneering stock price today i.e. is closed at $3.75,which is 55.78% down from its 52 week high and 10.95% up from its 52 week low.

    What is Immuneering's market capitalisation today?

    Immuneering market capitalisation is $0.00T as on .

    How to invest in Immuneering Stock (IMRX) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Immuneering on INDmoney app. Click on Buy button.

    What is the minimum amount required to buy Immuneering Stock (IMRX) from India?

    Indian investors can start investing in Immuneering (IMRX) shares with as little as ₹94.94999694824219 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹949.50 in Immuneering stock (as per the Rupee-Dollar exchange rate as on ). Based on Immuneering share’s latest price of $3.75 as on November 2, 2026 at 8:46 am IST, you will get 2.6667 shares of Immuneering. Learn more about fractional shares .

    What are the returns that Immuneering has given to Indian investors in the last 5 years?

    Immuneering stock has given -87.07% share price returns and 27.22% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?